Market Intelligence, Clinical Progress, and High-Purity Reagents for Psychiatric and Immunological Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VIPR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VIPR2 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View VIPR2 Products |
| Gene Delivery | VIPR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Optimized for functional receptor expression. |
View VIPR2 Products |
| Benchmark Ab | Anti-VIPR2 Recombinant Antibody Recombinant positive control for binding and flow cytometry assays. |
View VIPR2 Products |
| Validator | VIPR2 siRNA Set For knockdown verification in target specificity assays. |
View VIPR2 Products |
| Related Target A | VIPR1 Subfamily homolog. Crucial for selectivity and counter-screening assays. |
View VIPR1 Products |
| Related Target B | PAC1 Related Class B GPCR sharing ligand homology. Essential for off-target screening. |
View PAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Maintenance | Lentivirus-driven stable cell lines expressing full-length VIPR2 for functional assays. |
| Subfamily Off-Target Cross-Reactivity (VIPR1/PAC1) | Recombinant VIPR1 and PAC1 homolog proteins strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live VIPR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VIPR2 therapeutics is intensifying, with major players shifting focus from traditional peptides to highly selective small-molecule modulators and monoclonal antibodies. As first-generation therapies targeting Class B GPCRs reach the clinic, the next wave of R&D is targeting VIPR2 for its highly specific roles in psychiatric disorders (such as schizophrenia driven by VIPR2 microduplications) and oncology microenvironment regulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Antagonists) | Sosei Heptares, Academic Spin-offs | Schizophrenia, Cognitive Disorders | GPCR functional assay (cAMP accumulation) requiring stable VIPR2 cell lines. |
| Monoclonal Antibody | Biotech Innovators | Oncology, Autoimmune Diseases | Selectivity profiling against VIPR1/PAC1 (requires high-purity recombinant ECDs). |
| Peptide Mimetics | Pharmaceutical Corporates | Metabolic Diseases, Neuroprotection | Receptor internalization and beta-arrestin recruitment assays. |